Literature DB >> 12654968

Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese.

D K Y Chan1, M K P Lam, R Wong, W T Hung, D E L Wilcken.   

Abstract

BACKGROUND: The slow acetylator genotype for N-acetyltransferase 2 (NAT2 genotype) may be associated with PD in white subjects and the genotype is common in both white and Chinese populations. Whether there is a relationship between NAT2 genotype and PD in Chinese subjects is not known.
OBJECTIVE: To investigate the association between the slow acetylator genotype for N-acetyltransferase 2 and PD in a Chinese population.
METHODS: The authors obtained DNA samples and documented sex, age, and smoking history in 99 Chinese patients with PD and in 126 control subjects from two major Hong Kong hospitals. PCR-restriction fragment length polymorphism was used to identify M1, M2, and M3 mutant polymorphisms of the slow acetylator genotype for N-acetyltransferase 2. Logistic regression analyses were carried out to investigate the relationships between the different variables and PD.
RESULTS: The frequency of the slow acetylator genotype for N-acetyltransferase 2 in the PD group was significantly higher than that of the control group (68.7% vs 28.6%) with an OR of 5.53 (95% CI 3.08 to 9.92) after adjusting for age, sex, and smoking history. In a subgroup analysis smoking had no modifying effect on the association between genotype and PD.
CONCLUSIONS: There is a significant association between PD and the slow acetylator genotype for N-acetyltransferase 2 in Hong Kong Chinese. The OR found is among the highest reported so far in all susceptibility gene studies for PD in both Chinese and white subjects and provides evidence for a possible functional relationship between NAT2 slow acetylator genotype and PD in both racial groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654968     DOI: 10.1212/01.wnl.0000052787.87093.b8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Parkinson's disease in China.

Authors:  You-yong Tian; Cui-ju Tang; Jie Wu; Jun-shan Zhou
Journal:  Neurol Sci       Date:  2010-12-14       Impact factor: 3.307

Review 2.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

3.  Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.

Authors:  Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan
Journal:  BMC Med Genet       Date:  2012-03-17       Impact factor: 2.103

4.  Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women.

Authors:  N Palacios; M Weisskopf; K Simon; X Gao; M Schwarzschild; A Ascherio
Journal:  Parkinsonism Relat Disord       Date:  2010-03-20       Impact factor: 4.891

5.  Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease.

Authors:  José A G Agúndez; Antonio Luengo; Oscar Herráez; Carmen Martínez; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez; Elena García-Martín
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

Review 6.  Neurodegenerative disorders associated with diabetes mellitus.

Authors:  Michael Ristow
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

7.  N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease.

Authors:  Juergen Borlak; Stella Marie Reamon-Buettner
Journal:  BMC Med Genet       Date:  2006-03-29       Impact factor: 2.103

8.  Inferring haplotypes at the NAT2 locus: the computational approach.

Authors:  Audrey Sabbagh; Pierre Darlu
Journal:  BMC Genet       Date:  2005-06-02       Impact factor: 2.797

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.